Advertisement
U.S. markets open in 5 hours 49 minutes

Corvus Pharmaceuticals, Inc. (CRVS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.3000-0.0200 (-0.86%)
At close: 04:00PM EST
2.1500 -0.15 (-6.52%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close2.3200
Open2.2900
Bid0.0000 x 2200
Ask0.0000 x 1100
Day's Range2.2400 - 2.3250
52 Week Range0.6070 - 4.1900
Volume66,175
Avg. Volume209,972
Market Cap112.789M
Beta (5Y Monthly)1.04
PE Ratio (TTM)N/A
EPS (TTM)-0.6400
Earnings DateMar 26, 2024 - Apr 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.88
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CRVS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Corvus Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 05/06/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 years agoArgus Research
View more
  • GlobeNewswire

    Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

    Poster presentation unveils Corvus’ next-generation ITK inhibitor candidates designed to deliver precise T cell modulation for immunology indications Figure 1 Venn diagram illustrating different biological properties of the next-gen ITK inhibitors in T cell differentiation assays. BURLINGAME, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that preclinical data for soquelitinib, the Company’s lead

  • GlobeNewswire

    Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma

    Company on track to initiate soquelitinib Phase 3 registrational clinical trial in PTCLBURLINGAME, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for soquelitinib for the treatment of T cell lymphoma. Soquelitinib, the Company’s lead ITK inhibitor candidate, is expected to advance into a Phase 3 registrational clinica

  • GlobeNewswire

    Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer

    BURLINGAME, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the appointment of Jeffrey Arcara as Chief Business Officer. Mr. Arcara, who is a proven leader with more than 30 years of commercial experience in the biopharmaceutical industry, will be responsible for leading corporate strategy, business development, portfolio strategy, and new product planning. “Corvus is leading the development of ITK